SARS-CoV-2 Pre-exposure Prophylaxis With Ivermectin Retrospective Cohort Study

Grupo Rescue S.A.S República Dominicana

Status

Completed

Conditions

Covid19

Treatments

Drug: Ivermectin 6 Mg Oral Tablet

Study type

Observational

Funder types

NETWORK

Identifiers

NCT04832945

8953

Details and patient eligibility

About

This observational study, a multicenter retrospective cohort database study, carried out in two medical centers, Centro Medico Bournigal (CMBO) in Puerto Plata and Centro Medico Punta Cana (CMPC) in Punta Cana, Dominican Republic, sought to determine whether Ivermectin, at a weekly orally dose of 0.2 mg/kg, is an effective pre-exposure prophylactic method (PrEP) for the spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), in the healthcare workers. The study began on June 29, 2020 and ended on July 26, 2020 (4 weeks).

Enrollment

713 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Active workers from Centro Medico Bournigal (CMBO) and Centro Medico Punta Cana (CMPC) during the study.

Exclusion Criteria

Workers with positive Covid-19 RT-PCR prior to the start of the study
Those that did not take the first dose of Ivermectin the first week at the start of the study
Those that did not complied with at least 2 out of 4 weekly doses
Those that had greater than 14 days difference in days between two intakes Ivermectin